ArticleBMJ paediatrics open2025
Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants.
Article in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Acute viral bronchiolitis before and after implementation ofThe Lancet regional health. Europe · 2026Article
- Observational
- Review
- Dual Immunization Against RSV With RSVpreF and Nirsevimab.JAMA pediatrics · 2026Article
- Article
- Integrated follow-up of former extremely preterm infants: how to do it?European journal of pediatrics · 2025Review
- Nirsevimab Prophylaxis and Respiratory Syncytial Virus Hospitalizations Among Infants.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.
designRetrospective cohort study conducted during two identical epidemic seasons: 2023-2024 (before nirsevimab introduction) and 2024-2025 (after nirsevimab introduction).
settingMulticentre study involving five hospitals in Italy. PATIENTS: All infants under 1 year of age hospitalised for acute lower respiratory tract infection across two consecutive respiratory syncytial virus (RSV) seasons. We compared the number of RSV-positive hospitalisations (283 cases) and, among those admissions, clinical severity between the pre-nirsevimab and post-nirsevimab seasons, given live birth denominators at participating hospitals were stable. RSV-negative hospitalisations (79 cases) were analysed in parallel as a sensitivity analysis.
interventionThe study compared hospitalised infants eligible for RSV immunoprophylaxis during the 2024-2025 season who received nirsevimab, with those from the 2023-2024 season who did not receive nirsevimab (or received palivizumab, if indicated).
main outcome measuresThe primary outcome was the count of RSV-associated hospitalisation, with nirsevimab prophylaxis as the primary exposure, considering live birth denominators at participating hospitals were stable. Particular attention was given to whether gestational age modified the effectiveness of the prophylaxis. Secondary outcomes included measures of disease severity (eg, high-flow nasal cannula use, neonatal intensive care unit admission), adjusted for the effect of gestational age and other relevant covariates. Bayesian hierarchical regression models were used, with sensitivity analyses performed both in negative cases and using frequentist bootstrapped hierarchical models.
resultsMedian gestational age at birth was 39.7 (38.7-40.7) weeks in the no-prophylaxis group versus 37.3 (35.3-39.0) weeks in the nirsevimab group. Despite prophylaxis, lower gestational age was associated with an increased risk of hospitalisation (Bayesian posterior probability, 98.68%; maximum a posteriori HR 0.63; 95% highest density interval: 0.41-0.95). No RSV hospitalisations occurred between 40 and 90 days post-prophylaxis, suggesting a window of maximal effectiveness. Nirsevimab significantly reduced RSV-related hospitalisations and the need for non-invasive respiratory support.
conclusionsNirsevimab prophylaxis was associated with reduced hospitalisation and severity. However, protection waned in preterm infants, highlighting the need to investigate modified dosing strategies for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.